High-throughput studies further support this finding, showing that CD8+ T cells from patients with B-ALL can recognize and respond to neoantigens derived from fusion proteins, such as ETV6::RUNX1 (58). The gene discussed is CD8A; the disease is acute lymphoblastic leukemia.